#Ceo of ecrisper how to#
#Ceo of ecrisper free#

I realised that this was the perfect time for me to start graduate school and I joined Jennifer’s lab to conduct my PhD, under the co-supervision of David Savage, who is also a co-founder of Scribe.

#Ceo of ecrisper free#

And then CRISPR-Cas9 emerged and suddenly I was free to target anything I wanted.

#Ceo of ecrisper how to#

Yes! We had been working 80-hour weeks for 2 years trying to develop a code that could figure out how to bind zinc finger targets so that we could target any location in the genome. And then Jennifer Doudna and Emmanuelle Charpentier published that seminal paper on CRISPR-Cas9 in 2012, right? For two years I built huge unbiased libraries of zinc finger nucleases. I knew that trying to build the necessary technical skills would be crucial, so rather than going straight into graduate school, I joined Marcus Noyes’ lab at Princeton University that focused on engineering zinc finger nucleases. This really motivated my transition from wanting to be a doctor or an MD with a PhD, to wanting to build those missing tools. It still isn't today, and that's not a problem with medicine, but more a problem with not having the tools to do so. But in shadowing doctors in rural Maine, I quickly realised that most of medicine wasn't focused on treating the underlying causes of disease. I actually started out studying to be a medical doctor. Can you tell me how you ended up working in this area? You are one of the founders, along with Brett Staahl, David Savage, and Jennifer Doudna herself. Scribe Therapeutics spun out of Jennifer Doudna’s lab at UC Berkeley in 2018. CMN Webinar - CRISPR-based Control of Insect-borne Diseasesīenjamin Oakes PhD is co-founder and CEO of California-based gene-editing company Scribe Therapeutics, a spin-out from Nobel Laureate Jennifer Doudna's lab at University of California Berkeley.CMN Webinar - Controllable Genome Editing With Split-Engineered Base Editors.CMN Webinar - Deliver CRISPR to the Brain - A New Treatment Strategy for Mucopolysaccharidoses.Shanghai Bangyao Biotechnology Co., Ltd.It is hoped that with further research this novel approach will aid in drug discovery to provide effective treatment for Huntington’s disease. In addition, they hope that comparative data will provide the potential identify and investigate the effects of the CAG trinucleotide repeat expansion. Researchers from bit.bio suggest that utilizing ioGlutamatergic Neurons HTT 50CAG/WT and wild type ioGlutamatergic Neurons that do not contain the mutation in drug discovery will enable scientists to study the effects of novel treatments in a disease-relevant system with a genetically matched control. It adds depth to our broadening R&D cell type product pipeline, each product will transition to its own product line.” Our opti-ox TM1 technology allows the development of consistent and scalable biological standards that can support the evolution of a new generation of medicines.

The launch of our Huntington’s disease model provides the industry with an advanced cellular tool to support the study of a devastating condition with high unmet clinical needs. Mark Kotter, CEO and founder of bit.bio, explained: “bit.bio’s mission is coding cells for novel cures. In order to do this, bit.bio introduced a stable 50 ‘CAG’ repeat mutation in the Huntingtin gene in wild type ioGlutamatergic Neurons. To overcome this, researchers from bit.bio have created a consistent, scalable cell model that reproduces the condition in vitro. Previously, it has been challenging for scientists to engineer the precise disease-causing mutation in cells.

More specifically, ≥ 40 repeats of a ‘CAG’ DNA sequence. Huntington’s disease is a neurodegenerative condition that is caused by specific mutations in the Huntingtin gene. The ioDisease Model Portfolio uses iPSCs, which have been generated utilizing CRISPR/Cas9-based gene editing. This enables human diseases to be reproduced in vitro that can be matched to an isogenic wild type control. The technology behind this product is bit.bio’s ioDisease Model portfolio, which is a range of cells that have specific disease-associated mutations. The novel disease model approach – one of the first of its kind to be commercially available – is an exact replication of the genetics of Huntington’s disease. Researchers from bit.bio (Cambridge, UK) have announced the launch of their ioGlutamatergic Neurons HTT 50CAG/WT cells, which they hope will enable more effective drug discovery for Huntington’s disease.